2023 World Conference on Lung Cancer (Posters)-P2.13. Genomic Associations of Chemoimmunotherapy Outcomes in a Real-World Cohort of Small Cell Lung Cancer (SCLC) Patients

P2.13. Genomic Associations of Chemoimmunotherapy Outcomes in a Real-World Cohort of Small Cell Lung Cancer (SCLC) Patients - PDF(Slides)

Back to course

Pdf Summary

This study aimed to investigate the genomic associations of chemoimmunotherapy outcomes in a real-world cohort of small cell lung cancer (SCLC) patients. The researchers examined the mutational landscape of SCLC using next-generation sequencing and compared the outcomes of patients receiving combined platinum-based chemotherapy and PD-L1 inhibition, with or without immunotherapy, based on tumor mutational burden (TMB) status.<br /><br />The study included SCLC patients who underwent comprehensive genomic profiling (CGP) testing from 2011 to 2022. The patients' clinical data were derived from electronic health records and linked to genomic data from CGP tests. The researchers compared time to next treatment (TTNT) and overall survival (OS) between patients receiving first-line immunotherapy and chemotherapy versus chemotherapy alone, based on TMB status, using Cox proportional hazards models.<br /><br />The most common genomic alterations identified in SCLC patients were mutations in TP53, alterations in RB1, mutations in MLL2, alterations in PTEN, and MYCL1 amplification. Patients with TMB ≥10 mutations/mb receiving immunotherapy in combination with chemotherapy had a more favorable TTNT but similar OS compared to those receiving chemotherapy alone. Patients with TMB <10 mutations/mb receiving chemotherapy alone had similar TTNT but improved OS compared to those receiving immunotherapy plus chemotherapy.<br /><br />No significant differences in genomic alterations were observed between patients with different TTNT durations. The study findings suggest that high TMB may be a prognostic factor rather than a predictive one for immunotherapy response in SCLC.<br /><br />In conclusion, this real-world study provides insights into the genomic associations of chemoimmunotherapy outcomes in SCLC patients. Further research focusing on specific genomic alterations and RNA expression is needed to identify additional markers of chemoimmunotherapy effectiveness in SCLC.

Asset Subtitle

Ayman Ullah

Meta Tag

Speaker Ayman Ullah

Topic SCLC & Neuroendocrine Tumors: Biomarkers & Radiomics

Keywords

genomic associations

chemoimmunotherapy outcomes

small cell lung cancer

SCLC

next-generation sequencing

tumor mutational burden

comprehensive genomic profiling

time to next treatment

overall survival

genomic alterations